Single-centre target-trial emulation in 172 nintedanib initiators with fibrosing ILD: starting at 100 mg vs 150 mg twice daily was associated with 52.9 more days on treatment over 12 months and lower discontinuation risk (0.135 vs 0.281); FVC change was similar but imprecise.
RCTn = 172
Kaburaki et al. Low-dose vs standard-dose nintedanib at initiation in fibrosing interstitial lung disease: a target-trial emulation of treatment persistence and lung function